MARKSANS.NS
Strong BuyPremium GrowerAI neutralMarksans Pharma Limited · Healthcare · India · $1.6B cap · $7.4M/day traded
INR 307.85 -2.0% · close 15 Oct · scored 17 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
As of 17 Oct 2026, MoatMap's StockRank for Marksans Pharma Limited (MARKSANS.NS) is 93/100, ranked against 24,000+ stocks in 35 markets (Quality 81, Value 34, Momentum 81, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Marksans Pharma makes generic and over-the-counter medicines for the US, UK and Australia and has delivered strong quality metrics and share-price momentum. The business is well run for a generics maker, but its valuation is full relative to peers and generic pricing is fiercely competitive, which limits the margin of safety.
ABOUT MARKSANS PHARMA LIMITED
Read
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.5B | 21.7B | 26.1B | 29.4B | 16.7% | 31.7B | 35.6B | 39.8B | 16.4% |
| EPS (INR) | 6.41 | 6.92 | 8.40 | 9.22 | 12.9% | 11.41 | 12.55 | 14.07 | 23.5% |
| Shares | 446.7M | 453.2M | 453.2M | 453.2M | +1.4% | 453.2M | — | — | — |
| Debt | 1.2B | 2.4B | 3.2B | 3.4B | 40.8% | 3.4B | — | — | — |
| Equity | 17.5B | 20.7B | 24.7B | 30.2B | 20.1% | — | — | — | — |
| Op CF | 2.4B | 2.3B | 2.1B | 4.6B | 24.5% | 4.6B | — | — | — |
| Inv CF | -2.6B | -1.4B | -490.1M | -2.5B | — | — | — | — | — |
| Fin CF | 2.0B | -687.3M | -651.5M | -709.3M | — | — | — | — | — |
Above its 200-day average and 12% below its 52-week high.
Swung more than 54% of stocks we rank over the past year (44% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MARKSANS.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MARKSANS.NS | Marksans Pharma Limited(you) | $1.6B | 93 | Strong Buy |
| PFIZER.NS | Pfizer Limited | $1.9B | 85 | Strong Buy |
| SANOFI.NS | Sanofi India Limited | $752M | 90 | Strong Buy |
| SANOFICONR.NS | Sanofi Consumer Healthcare India Limited | $955M | 73 | Buy |
| GLAXO.NS | GlaxoSmithKline Pharmaceuticals Limited | $5.0B | 83 | Strong Buy |
| RUBICON.NS | Rubicon Research Limited | $2.9B | 71 | Buy |
| SENORES.NS | Senores Pharmaceuticals Limited | $645M | 69 | Buy |
| TTKHLTCARE.NS | TTK Healthcare Limited | $154M | 90 | Strong Buy |
| NGLFINE.NS | NGL Fine-Chem Limited | $186M | 79 | Buy |
| SMSPHARMA.NS | SMS Pharmaceuticals Limited | $463M | 54 | Hold |
Peer medians: ROE 11.7% · P/E 40.7x · Gross margin 59.4%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.